linjc16/ctgov huggingface dataset:
Use of Infrared Spectroscopy in Septic Arthritis Diagnosis

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to assess the ability of Fiber-optic Evanescent Wave Spectroscopy (FEWS) to discriminate synovial fluids samples of septic arthritis patients from other causes of joint effusion by analyzing ex vivo joint fluid samples collected during routine clinical care.

Official Title
-----------------
Use of Infrared Spectroscopy in Septic Arthritis Diagnosis

Conditions
-----------------
Joint Effusion

Intervention / Treatment
-----------------
* Other: infrared spectroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study patients over 18 year old, patients who received information about the protocol and have not expressed opposition to participate. Exclusion Criteria: patients opposing the study, patients aged below 18 year old Protected major (safeguard justice , trusteeship and guardianship) and persons deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: infrared spectroscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of the cause of joint effusion | The final diagnosis of the cause of joint effusion is made by the clinician based on the clinical and laboratory data : septic arthritis or other causes of arthritis. | through study completion, an average of 6 months |
Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity

Study Overview
=================
Brief Summary
-----------------
Checkrein deformity represents a dynamic claw toe deformity. Surgical intervention is the treatment of choice and many methods have been proposed. The purpose of this study is to evaluate the outcomes and complications of percutaneous segmental tenotomy of the toe flexor tendons.

Detailed Description
-----------------
The investigators reviewed fourteen patients with checkrein deformity who underwent surgery in our hospital between 1993 and 2010. Five patients received FHL and flexor digitorum longus (FDL) tenolysis at the musculotendinous junction; among them, two also underwent Z-plasty lengthening of the FHL tendon. Nine patients underwent percutaneous segmental toe flexor tenotomy. The Hallux Metatarsophalangeal- Interphalangeal Scale (Hallux MTP-IP scale) and Foot and Ankle Outcome Score (FAOS), English version LK1.0 self-explanatory questionnaire were used to evaluate the functional outcomes.

Official Title
-----------------
Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity

Conditions
-----------------
Claw Toe

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with checkrein deformity who underwent surgery in our hospital between 1993 and 2010. Exclusion Criteria: Patients who had static or rigid claw toe deformity Patients who had claw toe deformity secondary to neuromuscular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 73 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Claw Toe
Deep Brain Stimulation Follow-up After 10 Years

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the long-term effect of Deep Brain Stimulation (DBS) for patients with Parkinson's Disease. We have data for patients operated with DBS since 1998. We wish to examine the effect of stimulation on motor symptoms as well as make a follow-up on complications and side-effects related to treatment. We also wish to follow-up on the quality of life-studies made in the years 2003-2008.

Detailed Description
-----------------
Parkinson's Disease (PD) is caused by a progressive loss of dopamine-producing cells in substantia nigra in mesencephalon. PD is characterized by the symptoms resting tremor, rigidity and bradykinesia. Later in the course of the disease, patients develop gait- and balance symptoms. In the first years of the disease, the patients' symptoms are treated well with levodopa. As the disease develops and the loss of dopamine-producing cells grows, the physiological buffer-capacity for levodopa is lost and patients develop motor fluctuations in the shape of on-off symptoms and dyskinesias. Patients with these symptoms may benefit from implantation of electrodes in the subthalamic nucleus, which is stimulated by an pulse generator on the chest. A number of studies have found a long-term effect of DBS, but most of these studies have a follow-up time of no more than five years. Overall, these studies show a beneficial effect of DBS after five years: The patients need less medication, the number of off-periods is decreased and they score lower on the Unified Parkinson Disease Rating Scale, part three. However, the axial symptoms and the bradykinesia progress. As of yet, few studies examine the effect of Deep Brain Stimulation after 10 years. In our study we wish to examine the effect of DBS for all patients operated at Aarhus University Hospital in the years 1998-2002, which gives us a follow-up time of 10-14 years.

Official Title
-----------------
STN-DBS Retrospective/Prospective Study With a Follow-up Time of Minimum 10 Years

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Parkinson's Disease treated with DBS at Aarhus University Hospital in the years 1998-2002. Exclusion Criteria: Dementia, i.e. MMSE<24 DBS removed Deceased
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson's Disease, DBS, 10-14 years<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's Disease, Stimulation, Deep Brain, Study, Follow-Up, Adverse Effects
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Study Overview
=================
Brief Summary
-----------------
The objective of this survey is to confirm the safety of Suglat Tablets

Detailed Description
-----------------
The objective of this survey is to confirm the safety and efficacy of Suglat Tablets for long-term use over 3 years. Specify the effects of Suglat Tablets on the cardiovascular system, incidence rates of malignant tumor, and their risk factors. Investigate the occurrence of adverse drug reactions. Specify factors that may possibly influence the safety and efficacy of Suglat Tablets. <Items of interest> Hypoglycemia Genital infection Urinary tract infection Polyuria and pollakiuria Adverse events related to a decrease in body fluids (dehydration, etc.) Malignant tumor Cardiovascular diseases

Official Title
-----------------
Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: ipragliflozin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with type 2 diabetes who first use Suglat Tablets during the period from July 17, 2014 to July 16, 2015 Exclusion Criteria: off-label use patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suglat group<br>Tablets | Drug: ipragliflozin<br>* Tablets<br>* Other names: Suglat;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiovascular adverse events |  | Up to 3 years | 
| Incidence of malignant tumor |  | Up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety developed by adverse events and laboratory tests |  | Up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Suglat, SGLT-2 inhibitor, Ipragliflozin L-Proline, ASP1941 long-term use
Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV

Study Overview
=================
Brief Summary
-----------------
Four focus groups , each of 10-15 males, ages 20-50 years old, MSM will be conducted by a medical sociologist. Two groups will be HIV negative participants and two groups of HIV positive MSM. Every group will meet for two hours. The focus group will be recorded and the collected data will be processed further for evaluation and extraction of the relevant information. The volunteers will sign an inform consent prior to entrance to the study.

Detailed Description
-----------------
The questions that will be discussed during the focus groups: The first sexual contact with a male, what is risk, risk taking behavior, control over your daily life, self esteem and evaluation, risk denial.

Official Title
-----------------
Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV - Focus Groups, Observational Study

Conditions
-----------------
MSM, HIV Infections, Risky Behaviors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20-50 MSM, willing to participate Agree to sign an inform consent Exclusion Criteria: No exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 20-50 YEARS OLD MSM<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MSM, focus group, HIV, risk-taking, risk-denial, signature on inform consent, willing to participate, MSM either HIV positive or negative, age 20-50 years old
A Study of LY2157299 Monohydrate in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study involves a single dose of 150 milligram (mg) of radiolabeled LY2157299 monohydrate in healthy participants. The study will determine how the body eliminates the radioactivity and LY2157299 monohydrate. Participants must be healthy surgically sterile or postmenopausal females, or sterile males. This study is approximately 8 to 15 days.

Official Title
-----------------
Disposition of [14C]-LY2157299 Monohydrate Following Oral Administration in Healthy Subjects

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: [^14C]-LY2157299


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy surgically sterile females, postmenopausal females, or sterile males Body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2) Have venous access sufficient to allow for blood sampling Exclusion Criteria: Have known allergies to LY2157299, related compounds or any components of the formulation Have an abnormal blood pressure as determined by the investigator Have participated in a [^14C]-study within the last 6 months prior to admission for this study

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: [^14C]-LY2157299<br>Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug | Drug: [^14C]-LY2157299<br>* [^14C]-LY2157299 monohydrate administered as oral solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary and Fecal Excretion of LY2157299 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered |  | Pre-dose through Day 15 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Maximum Observed Concentration (Cmax) |  | Pre-dose through Day 14 | 
| Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Time of Maximum Observed Concentration (Tmax) |  | Pre-dose through Day 14 | 
| Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Area Under the Concentration-Time Curve from Time Zero to the Last Timepoint with a Measurable Concentration (AUC 0 to tlast) |  | Pre-dose through Day 14 | 
| Relative Abundance of LY2157299 and the Metabolites of LY2157299 in Urine and Feces |  | Pre-dose through Day 14 | 
| Relative Abundance of LY2157299 and the Metabolites of LY2157299 in Plasma |  | Pre-dose through Day 14 |
Rapid Urease Test for Diagnosis Helicobacter Pylori Infection

Study Overview
=================
Brief Summary
-----------------
Nowadays, the gold standard examinations for diagnosing H. pylori infection are histopathology and culture examination. However, those examinations take long preparation so they are not suitable to be applied in daily practice. In progress, another examination is being developed to detect urease enzyme from tissue biopsy. It is relatively faster in diagnosing H. Pylori infection. Some commercial urease tests which are available in Indonesia are Helicotec® and Pronto Dry®. This study aims to determine the effectivity of Helicotec® in diagnosing H. pylori infection. It is expected to be scientific evidence that can be used as the basis daily routine of urease test in diagnosing H. Pylori infection.

Detailed Description
-----------------
This study is a diagnostic study. There will be 97 dyspepsia patients who met the inclusion and exclusion criteria. They will answer the questionnaire about personal data and examined physically. They will also undergo endoscopy, biopsy, and urease test using Helicotec®

Official Title
-----------------
Effectiveness of Rapid Urease Test (Helicotec) for The Diagnosis of Helicobacter Pylori Infection in Dyspepsia Patients in Endoscopy Centre

Conditions
-----------------
Helicobacter Pylori Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult (18-55 years old), Diagnosed with dyspepsia, Indicated for endoscopy, Agreed to participate in the study and signed the informed consent. Exclusion Criteria: Pregnancy and breastfeeding woman, Patients with alarm symptom, History taking of antibiotics (amoxicillin, clarithromycin, levofloxacin), H2 receptor antagonist, proton pump inhibitor, misoprostol, sucralfat, bismuth, NSAIDs, steroid, rheumatoid drug within the last 2 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectivity of Helicotec | Obtained the sensitivity and specificity value | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
helicobacter pylori, urease test, helicotec
Anticipated and Perceived Benefits Following Hepatitis C Treatment

Study Overview
=================
Brief Summary
-----------------
The study is both qualitative and quantitative, gathering patient's perceptions of HCV treatment benefits before and after HCV treatment by administering surveys and conducting in-depth qualitative patient interviews. The study seeks to understand all anticipated and actual benefits patients perceive before and after viral eradication.

Detailed Description
-----------------
This study employs a mixed methods (qualitative and quantitative) pre-post study design utilizing in-depth qualitative interviews and patient reported outcome surveys. Pre-treatment surveys and interviews will be conducted before HCV therapy commences to understand all potential psychological, social, physical and medical consequences perceived to be related to HCV and the patients' anticipation (hope for) of improvements in these factors after viral eradication. Post-treatment surveys and interviews will occur 4 to 8 months after treatment ends to examine long-term treatment benefits, i.e., changes in HCV-related factors, such as symptoms, functioning, and health status.

Official Title
-----------------
A Qualitative and Quantitative Evaluation of Patients' Anticipated and Perceived Treatment Benefits Following HCV Viral Eradication

Conditions
-----------------
Hepatitis C, Hepatitis C, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 21 or older English-speaking Any genotype Any treatment duration (e.g. 8, 12, or 24 weeks) Has been written a prescription for a sofosbuvir (SOF)-containing regimen. Exclusion Criteria: Currently listed for liver transplant; post-liver transplant

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyze changes in patient perceptions through qualitative interviews before and after HCV treatment. | To conduct a pre-post qualitative analysis that will evaluate changes in a broad range of patients' perceptions of psychological, social, and physical effects associated with HCV and viral cure collected through qualitative interviews. | 1 Year | 
| Evaluate pre-post survey change in patient reported HCV symptoms and other factors. | To conduct a pre-post survey evaluation of change in patient-reported HCV symptoms, functioning, and health perceptions associated with HCV and viral cure. | 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis C, Patient-Reported Outcomes, DAA Treatment, Qualitative, Mixed methods
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Study Overview
=================
Brief Summary
-----------------
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation. Patients will be randomized to one of three fixed dose levels of SC MNTX.

Official Title
-----------------
A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Conditions
-----------------
Bowel Dysfunction

Intervention / Treatment
-----------------
* Drug: SC MNTX
* Drug: SC MNTX
* Drug: SC MNTX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have advanced medical illness (cancer, HIV, etc) and be receiving palliative care Must be on opioid medication for at least 2 weeks with no expectation of significant change in regimen Must have constipation Must be 18 yrs or older Exclusion Criteria: Concurrent use of medications other than opioids which might interfere with gastrointestinal motility Patients who received any experimental drug in the last 30 days Patients with active peritoneal cancer (ovarian, etc.) Patients with active diverticulitis or diverticulosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: SC MNTX<br>* Dose 1<br>|
| Experimental: Arm 2<br> | Drug: SC MNTX<br>* Dose 2<br>|
| Experimental: Arm 3<br> | Drug: SC MNTX<br>* Dose 3<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who have a bowel movement within four hours of dosing | To access the efficacy of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation. | Up to 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subject with Adverse Events | To access the tolerability of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation. | Up to 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opioid-induced bowel dysfunction